comscoreTalzenna Patient-Reported Outcomes

Talzenna Patient-Reported Outcomes

Jennifer Litton, MD, discusses results from the EMBRACA trial, quality of life for people treated with Talzenna, and why it's a good option for certain people.
Sep 17, 2020

At the American Association for Cancer Research virtual annual meeting, Dr. Litton presented results from the EMBRACA trial, looking at using Talzenna (chemical name: talazoparib), a type of medicine called a PARP inhibited, to treat advanced-stage HER2-negative breast cancer in people with a BRCA1 or BRCA2 mutation. She joins us today to talk about the results, especially the patient-reported outcomes, which showed that people treated with Talzenna had better quality of life than people treated with chemotherapy.

Listen to the podcast to hear Dr. Litton explain:

  • what a PARP inhibitor is and how it works

  • how quality of life was better for people treated with Talzenna compared to chemotherapy

  • why she thinks Talzenna is a good treatment option for people diagnosed with metastatic HER2-negative breast cancer who also have a BRCA1 or a BRCA2 mutation

About the guest
Jennifer Litton headshot
Jennifer Litton, MD

Dr. Jennifer Litton is a board-certified medical oncologist and professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston, where she is also vice president of clinical research. She also is a member of the Breast Immuno-Oncology Task Force of the National Cancer Institute.

— Last updated on June 29, 2022, 2:46 PM

Support to produce more content like this

Your donation goes directly to what you read, hear, and see on